. Author manuscript; available in PMC: 2016 Apr 1.

Published in final edited form as: Arthritis Care Res (Hoboken). 2015 Apr;67(4):457–466. doi: 10.1002/acr.22483

Table 3.

Adjusted risk of hyperlipidemia based on DMARD use- Propensity score trimmed cohort

Comparison^a	Treatment	Sample size	Events	HR (95% CI)^b
TNF-α inhibitors vs Methotrexate	Methotrexate	7177	158	Reference
TNF-α inhibitors vs Methotrexate	TNF-α inhibitors	874	33	1.18 (0.80–1.73)
Hydroxychloroquine vs Methotrexate	Methotrexate	7232	164	Reference
Hydroxychloroquine vs Methotrexate	Hydroxychloroquine	5632	91	0.75 (0.58–0.98)
Other non-biologic DMARDs vs Methotrexate	Methotrexate	7205	160	Reference
Other non-biologic DMARDs vs Methotrexate	Other DMARDs	1893	44	1.41 (1.01–1.98)

Abbreviations: CI- Confidence interval, DMARDs- Disease modifying anti-rheumatic drugs, HR- Hazard ratio, TNF- Tumor necrosis factor.

TNF-α inhibitors include adalimumab, certolizumab, etanercept, infliximab, and golimumab. Other non-biologic DMARDs include auranofin, injectable gold, penicillamine, sulfasalazine, minocycline, azathioprine, leflunamide, cyclophosphamide and cyclosporine.

Propensity score decile stratification was used to derive hazard ratios after trimming.